Supernus Pharmaceuticals
SUPN
43.05
+0.22
+0.51%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
43.05
+0.22
+0.51%
Live - 5344 symbols - heartbeat 48s ago
· 2026-10-08 04:02
Pre-market
42.45
-1.39%
After-hours
43.05
0.00%
- Market cap
- 2.51B
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 13%
Reader sentiment
Are you bullish or bearish on SUPN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 104.58% -0.14pp
- Institutions
- 398 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund73.59%
Hedge Fund24.03%
Individual/Insider4.33%
Public Company2.50%
VC/PE Fund1.78%
Government Pension Fund1.18%
Private Company0.73%
Insurance Company0.72%
Top holders as of 2026-06-30
BlackRock
16.09% · 9.35M sh
Millennium Management LLC
6.63% · 3.85M sh
Vanguard Portfolio Management, LLC
5.69% · 3.31M sh
Vanguard Capital Management, LLC
4.99% · 2.90M sh
Armistice Capital LLC
4.55% · 2.65M sh
State Street Global Advisors
4.23% · 2.46M sh
Macquarie Investment Management Business Trust
4.09% · 2.38M sh
Jack Khattar
3.81% · 2.22M sh
Dimensional Fund Advisors
3.58% · 2.08M sh
Geode Capital Management, LLC
2.70% · 1.57M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Jack Khattar | Founder, President, CEO, Secretary & Director | 3.81% |
| Charles Newhall | Independent Chairperson | 0.21% |
| Frederick Hudson | Independent Director | 0.10% |
| Georges Gemayel | Independent Director | 0.05% |
| Carrolee Barlow | Independent Director | 0.05% |
| Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | 0.03% |
| Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | 0.03% |
| Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | 0.02% |
| Timothy Dec | Senior Vice President | 0.02% |
| William Horich | Senior Vice President of Marketing & Market Access | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-11 | Jack Khattar | Founder, President, CEO, Secretary & Director | Derivative Exercise and Sale | -12,642 | $46.57 |
| 2026-08-11 | Jack Khattar | Founder, President, CEO, Secretary & Director | Derivative Exercise and Retained | +17,207 | -- |
| 2026-08-11 | Timothy Dec | Senior Vice President | Derivative Exercise and Sale | -604 | $46.57 |
| 2026-08-11 | Timothy Dec | Senior Vice President | Derivative Exercise and Retained | +646 | -- |
| 2026-08-11 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Sale | -1,158 | $46.57 |
| 2026-08-11 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Retained | +1,342 | -- |
| 2026-08-11 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -363 | $46.57 |
| 2026-08-11 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +387 | -- |
| 2026-08-11 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Derivative Exercise and Sale | -797 | $46.57 |
| 2026-08-11 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Derivative Exercise and Retained | +853 | -- |
| 2026-07-28 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Derivative Acquisition | +29,849 | -- |
| 2026-07-28 | Timothy Dec | Senior Vice President | Other Derivative Acquisition | +1,250 | -- |
| 2026-07-28 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Other Derivative Acquisition | +2,500 | -- |
| 2026-07-28 | Jonathan Rubin | Senior VP of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +750 | -- |
| 2026-07-28 | Frank Mottola | Senior Vice President of Quality, GMP Operations & Information Technology | Other Derivative Acquisition | +1,650 | -- |
| 2026-03-17 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Derivative Exercise and Sale | -107,250 | $27.94–50.73 |
| 2026-03-16 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Intent to Sell (Form 144) | -57,250 | $50.21 |
| 2026-03-15 | Padmanabh Bhatt | Chief Scientific Officer & Senior VP of Intellectual Property | Intent to Sell (Form 144) | -50,000 | $49.91 |
| 2026-03-12 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Acquisition | +12,500 | -- |
| 2026-03-12 | Jack Khattar | Founder, President, CEO, Secretary & Director | Other Disposition | -12,500 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:02:46 · For reference only, not investment advice and not tailored to your situation.